FMP
NASDAQ
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.
0.29 USD
0.0023 (0.793%)
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
Date
Revenue
Earnings
Estimated Earnings
Surprise
No data found!